Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Mehta R, et al. – Research published in Transplantation and Cellular Therapy shows better outcomes for matched unrelated donor and matched sibling donor hematopoietic cell transplantation (HCT) than haploidentical donor HCT when using post-transplant cyclophosphamide for graft-versus-host disease prevention in a single center study.
Murthy GSG, et al. – Research published in JAMA Oncology finds relapse and disease-free survival advantages when using younger matched unrelated donors over older matched sibling donors for patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome.
Khera N, et al. – Research presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition shows that rates of autologous and allogeneic hematopoietic cell transplants (HCT) have increased more rapidly among African American, Hispanic, and other underserved populations than among non-Hispanic whites from 2009 to 2018. However, a challenge still exists to close the gaps in overall survival for African American and other pediatric patients.